News
BNR
34.00
+11.04%
3.38
Weekly Report: what happened at BNR last week (0202-0206)?
Weekly Report · 3h ago
Weekly Report: what happened at BNR last week (0126-0130)?
Weekly Report · 02/02 10:12
Weekly Report: what happened at BNR last week (0119-0123)?
Weekly Report · 01/26 10:12
Burning Rock Biotech Breast Cancer NGS CDx Kit Enters CMDE Priority Review Channel
Reuters · 01/26 07:13
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/23 17:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/22 17:05
Weekly Report: what happened at BNR last week (0112-0116)?
Weekly Report · 01/19 10:17
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/14 17:05
Weekly Report: what happened at BNR last week (0105-0109)?
Weekly Report · 01/12 10:16
Burning Rock Biotech Granted U.S. Patent for ELSA-seq Liquid Biopsy Technology
Reuters · 01/06 06:29
Burning Rock Biotech CEO Yusheng Han purchases $811,721 of ADSs
TipRanks · 01/05 10:20
Weekly Report: what happened at BNR last week (1229-0102)?
Weekly Report · 01/05 10:11
Burning Rock Biotech CEO Purchases $811,721 in Company ADSs
Reuters · 01/05 06:16
Burning Rock Announces Founder’s Purchase of Its ADSs
Barchart · 01/05 00:16
Weekly Report: what happened at BNR last week (1222-1226)?
Weekly Report · 12/29/2025 10:11
Burning Rock Biotech Shareholders Approve All Resolutions at 2025 AGM
TipRanks · 12/23/2025 11:28
Burning Rock Biotech Ltd. Held Annual General Meeting
Reuters · 12/23/2025 04:04
Burning Rock Announces Results of 2025 Annual General Meeting
Barchart · 12/22/2025 22:04
Weekly Report: what happened at BNR last week (1215-1219)?
Weekly Report · 12/22/2025 10:10
Burning Rock Biotech Hosts Global Webinar on CAP and CLIA Accreditation
Reuters · 12/18/2025 07:37
More
Webull provides a variety of real-time BNR stock news. You can receive the latest news about Burning Rock Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BNR
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.